Cover Image
市場調查報告書

癌症治療的微管蛋白抑制劑的全球市場和臨床實驗趨勢

Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024

出版商 KuicK Research 商品編碼 603341
出版日期 內容資訊 英文 225 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症治療的微管蛋白抑制劑的全球市場和臨床實驗趨勢 Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024
出版日期: 2018年02月01日 內容資訊: 英文 225 Pages
簡介

本報告提供癌症治療的微管蛋白抑制劑市場相關調查,微管蛋白抑制劑概要,作用機制,臨床實驗平台下的藥品,價格分析,成長促進因素及課題分析,各企業、階段臨床實驗趨勢,競爭情形,主要企業簡介等,總括性彙整。

第1章 微管 - 癌症治療的標的

  • 概要
  • 癌症治療的微管蛋白抑制劑
    • 微管穩定化蛋白質
    • 微管不穩定化蛋白質

第2章 微管蛋白抑制劑的作用機制和抗性機構

  • 作用機制
  • 微管粘合劑的抗性機構

第3章 微管所扮演的角色和細胞壓力的工作

  • 癌症治療的微管蛋白的變化
  • 壓力反應的微管蛋白的細胞骨骼

第4章 癌症惡性度的預測的微管蛋白所扮演的角色

第5章 微管蛋白抑制劑的價格和劑量

  • Doceraxel
  • Trastuzumab Emtansine
  • Abraxane
  • Brentuximab Vedotin
  • Cabazitaxel

第6章 微管蛋白抑制劑市場分析

  • 概要
  • 微管蛋白抑制劑的銷售額

第7章 微管蛋白抑制劑的臨床實驗平台:概要

第8章 微管蛋白抑制劑的臨床實驗平台:各企業、階段

  • 調查
  • 前臨床檢驗
  • 臨床
  • 第I層實驗(階段I)
  • 第II層實驗(階段II)
  • 第II/III層實驗(階段II/III)
  • 第III層實驗(階段III)
  • 預註冊

第9章 已上市的微管蛋白抑制劑的考察

  • Docetaxel (Taxotere)
  • Trastuzumab Emtansine (Kadcyla)
  • Vinflunine (Javlor)
  • 白蛋白結合紫杉醇 (Abraxane & Coraxane)
  • Cabazitaxel (Jevtana)
  • Brentuximab Vedotin (Adcetris)
  • 紫杉醇高分子微胞配方 (Cynviloq & Genexol-PM)
  • 紫杉醇微脂體 - Sun Pharma Advanced Research Company
  • 紫杉醇微脂體 - LIPUSU
  • 奈米粒子紫杉醇

第10章 市場動態

  • 市場參數
  • 商品化的課題

第11章 微管蛋白抑制劑的未來展望

第12章 競爭環境

  • Abraxis Biosciences
  • Agensys
  • Amgen
  • Celgene
  • Eagle Pharmaceuticals
  • Endocyte
  • Genentech
  • Immunogen
  • Modra Pharmaceuticals
  • Pierre Fabre
  • Roche
  • Sanofi-Aventis
  • Seattle Genetics
  • Tocris Bioscience
目錄

"Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024" report gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of tubulin inhibitors in the cancer therapy. Report highlights the clinical development of more than 70 cancer tubulin inhibitors in pipeline and shares in-depth dosage/price analysis of 10 cancer tubulin inhibitors commercially available in the market.

"Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024" Report highlights:

  • Clinical Insight on 70 Tubulin Inhibitors in pipeline
  • Dosage & Price Analysis of 10 Commercialized Drugs
  • Patent Approval, Expiry Year & Market Sales Indicators
  • Patent Analysis of Key Drugs
  • Global Cancer Tubulin Inhibitors Clinical Pipeline by Company & Phase
  • Future Perspective of Cancer Tubulin Inhibitors

Cancer therapy has been one of the most extensive fields of research and development which acquires a vast portion of global therapeutic market. Development and commercialization of various advance cancer therapeutics such as targeted therapies and immunotherapies have been providing evidences of the rapid growth of cancer therapy market. However such chemotherapies follow a complex mechanism of action as they intend to target the DNA of the cancer cell and fail to achieve that target completely leading to generation of several adverse effects and drug resistances. Thus, such cancer therapies are said to be less effective in cancer treatment and thus leading to unmet medical needs of the patients.

Recently developed Tubulin Inhibitors have proven to be one of the unique cancer therapeutics as they directly target the tubulin fibers which are involved in division of cancer cells overcoming the major limitation of other cancer therapeutics. Target of Tubulin Inhibitors are microtubules which are a component of a cell involved in a process of cell division called mitosis. During mitosis cell divides to form identical cells by separating chromosomes and this separation of chromosomes is carried out by microtubules. Thus, Tubulin inhibitors stop cancer cells division which further increases the feasibility to remove cancer. Tubulin inhibitors are widely used due to their superiority against other cancer therapeutics such as better efficacy, negligible adverse effects and high specificity. Therefore, a wide range of investors and market players are attracted towards this class of anti-cancer drugs and are actively supporting the production and commercialization of tubulin inhibitors for cancer therapy.

Tubulin Inhibitors already have a great presence in the global cancer therapy market with more than 10 marketed products. Sales data of these tubulin inhibitors clearly indicates that they are widely accepted for clinical use. Moreover, the revenues generated by the major market players of tubulin inhibitors have further encouraged other large as well as small scale pharmaceutical companies to enhance research, development and commercialization of more tubulin inhibitors.

Global Tubulin inhibitor market is set to grow exponentially in coming four to five years due to the presence of a wide range of promising candidates in the later phases of clinical trials. Additionally, increase in cancer prevalence and unmet medical needs of cancer patients will increase the customer base for tubulin inhibitors and will further drive the global tubulin inhibitor market. Furthermore, after the commercial success of tubulin inhibitors in the developed countries, the tubulin inhibitor market is highly opportunistic for the developing countries as well, expanding the market globally.

Continuous and active research by the scientific community to produce unique tubulin inhibitors and acquiring better knowledge of their importance in cancer management are the major factors which have led to higher investments from both public and private sectors to encourage the development of tubulin inhibitors. Huge support for development and commercialization of tubulin inhibitors suggests global tubulin inhibitor market will grow continuously in the coming future and tubulin inhibitors are here to stay in the cancer therapy market.

Table of Contents

1. Microtubules - Moving Target in Cancer Therapy

  • 1.1 Overview
  • 1.2 Tubulin Inhibitors for Cancer Treatment
    • 1.2.1 Microtubule Stabilizing Proteins
    • 1.2.2 Microtubule Destabilizing Proteins

2. Mechanism of Action & Mechanism of Resistance of Tubulin Inhibitors

  • 2.1 Mechanism of Action
  • 2.2 Mechanism of Resistance to Microtubule Binding Agents

3. Microtubules & Their Role in Cellular Stress in Cancer

  • 3.1 Tubulin Alterations in Cancer
    • 3.1.1 Changes in Tubulin Isotype Composition
    • 3.1.2 Tubulin Post Translational Modifications
    • 3.1.3 Microtubule Associated Proteins (MAP)
  • 3.2 Tubulin Cytoskeleton in Stress Response

4. Prognostic Role of Tubulin for Prediction of Cancer Aggressiveness

  • 4.1 Non Small Cell Lung Cancer
  • 4.2 Prostate Cancer
  • 4.3 Breast Cancer
  • 4.4 Colorectal Cancer
  • 4.5 Ovarian Cancer

5. Price & Dosage Analysis of Tubulin Inhibitor Drugs

  • 5.1 Docetaxel
  • 5.2 Trastuzumab Emtansine
  • 5.3 Abraxane
  • 5.4 Brentuximab Vedotin
  • 5.5 Cabazitaxel

6. Market Analysis of Tubulin Inhibitors

  • 6.1 Overview
  • 6.2 Global Sales of Tubulin Inhibitors Drugs

7. Global Cancer Tubulin Inhibitors Clinical Pipeline Overview

8. Global Cancer Tubulin Inhibitors Clinical Pipeline by Company & Phase

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Clinical
  • 8.4 Phase-I
  • 8.5 Phase-II
  • 8.6 Phase-II/III
  • 8.7 Phase-III
  • 8.8 Preregistration

9. Marketed Cancer Tubulin Inhibitors Clinical Insight

  • 9.1 Docetaxel (Taxotere)
  • 9.2 Trastuzumab Emtansine (Kadcyla)
  • 9.3 Vinflunine (Javlor)
  • 9.4 Albumin-Bound Paclitaxel (Abraxane & Coraxane)
  • 9.5 Cabazitaxel (Jevtana)
  • 9.6 Brentuximab Vedotin (Adcetris)
  • 9.7 Paclitaxel Polymeric Micelle Formulation (Cynviloq & Genexol-PM)
  • 9.8 Paclitaxel Liposomal - Sun Pharma Advanced Research Company
  • 9.9 Paclitaxel Liposomal (Lipusu)
  • 9.10 Paclitaxel Nanoparticle (Nanoxel)

10. Global Cancer Tubulin Inhibitors Market Dynamics

  • 10.1 Favorable Market Parameters
  • 10.2 Commercialization Challenges

11. Future Perspective of Cancer Tubulin Inhibitors

12. Competitive Landscape

  • 12.1 Abraxis Biosciences
  • 12.2 Agensys
  • 12.3 Amgen
  • 12.4 Celgene
  • 12.5 Eagle Pharmaceuticals
  • 12.6 Endocyte
  • 12.7 Genentech
  • 12.8 Immunogen
  • 12.9 Modra Pharmaceuticals
  • 12.10 Pierre Fabre
  • 12.11 Roche
  • 12.12 Sanofi-Aventis
  • 12.13 Seattle Genetics
  • 12.14 Tocris Bioscience

List of Figures

  • Figure 1-1: Structure of Microtubule
  • Figure 1-2: Types of Tubulin Inhibitors for Cancer Treatment
  • Figure 3-1: Pathways for the Development of Cancer by Tubulin Alterations
  • Figure 3-2: Post Translational Modifications in Tubulin Structure
  • Figure 3-3: Structural Representation of Microtubule Associated Proteins
  • Figure 3-4: Tubulin Response to Cytoskeleton Stress
  • Figure 5-1: Docetaxel - Patent Approval & Expiry Year
  • Figure 5-2: Docetaxel - Available Concentrations mg/ml
  • Figure 5-3: Docetaxel - Average Dosage Analysis in Breast Cancer Therapy (mg/m2)
  • Figure 5-4: Cost of Docetaxel Drug for the Concentration of 10 mg/ml, for 2 Milliliters, 8 Milliliters & 16 Milliliters, Respectively (US$), 2017
  • Figure 5-5: Cost of Docetaxel Drug for the Concentration of 20 mg/ml, for 1 Milliliters, 4 Milliliters, 8 Milliliters & 10 Milliliters, Respectively (US$), 2017
  • Figure 5-6: Cost of Docetaxel Drug for the Concentration of 40 mg/ml, for 0.5 Milliliters, & 2 Milliliters, Respectively (US$), 2017
  • Figure 5-7: Docetaxel - Average Breast Cancer Treatment Cost (US$/Cycle), 2017
  • Figure 5-8: Docetaxel - Average Lung Cancer Therapy Cost Analysis (US$/Cycle), 2018
  • Figure 5-9: Trastuzumab Emtansine - Patent Approval & Expiry Year
  • Figure 5-10: Trastuzumab Emtansine - Average Dosage Analysis (mg/Dose)
  • Figure 5-11: Available Different Concentrations of Trastuzumab Emtansine (mg)
  • Figure 5-12: Trastuzumab Emtansine - Price by Concentration (US$), 2017
  • Figure 5-13: Trastuzumab Emtansine - Vials Used in Metastatic Breast Cancer Treatment (By Number)
  • Figure 5-14: Trastuzumab Emtansine - Average Treatment Cost Analysis (US$), 2017
  • Figure 5-15: Abraxane - Patent Approval Year for Various Cancer Indications & Expiration Year
  • Figure 5-16: Abraxane Dosage Analysis by Indication (mg/m2)
  • Figure 5-17: Cost of Abraxane Intravenous Solution of 100 mg, US$
  • Figure 5-18: Abraxane - Cancer Treatment Cost Analysis per Cycle (US$), 2017
  • Figure 5-19: Brentuximab Vedotin - Patent Approval & Expiry Years in US
  • Figure 5-20: Brentuximab Vedotin - Patent Approval & Expiry Years in Europe
  • Figure 5-21: Price of Brentuximab Vedotin Drug for Per Vial of 50 mg & For 7 Cycles Treatment, (US$), 2017
  • Figure 5-22: US - Brenuximab Vedotin Price Analysis, (US$), 2017
  • Figure 5-23: US - Brenuximab Vedotin Treatment Expenditure (US$), 2014
  • Figure 5-24: US - Brenuximab Vedotin Treatment Cost (US$), 2017
  • Figure 5 25: Cabazitaxel - Price of Drug per Cycle in US$ & Patent Expiration Year
  • Figure 5-26: Cost of Jevtana Intravenous Solution & Per Unit Cost, US$, 2017
  • Figure 6-1: Global Sales of Docetaxel Drug (US$ Million), 2015 & 2016
  • Figure 6-2: Global - Trastuzumab Emtansine Sales Revenue, US$ Millions, 2013 & 2016
  • Figure 6-3: Global - Abraxane Sales US$ Million, 2014-2017*
  • Figure 6-4: Global - Brenuximab Vedotin Sales (US$ Million), 2014-2017
  • Figure 6-5: Global - Blinatumumab Half Yearly Sales (US$ Million), 2015-2017
  • Figure 6-6: Global - Sales of Cabazitaxel Drug, US$ million, 2015 - 2017*
  • Figure 7-1: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
  • Figure 7-2: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
  • Figure 7-3: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
  • Figure 7-4: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
  • Figure 10-1: Favorable Market Parameters for Tubulin Inhibitors Development
  • Figure 10-2: Challenges to the Market Growth of Tubulin Inhibitors

List of Tables

  • Table 3-1: Clinical Studies of Tubulin Isotype in Drug Resistance
  • Table 5-1: Trastuzumab Emtansine Price Analysis
  • Table 5-2: Efficacy Results of Brentuximab Vedotin in Hodgkin Lymphoma Patients
Back to Top